Siren Biotechnology focuses on combining AAV gene therapy with cytokine immunotherapy to develop innovative treatments for cancer.
Siren Biotechnology has raised $8.0M in total funding. The most recent round was Grant. The last funding was announced in June 2026.
Siren Biotechnology's investors include Founders Fund, Lux Capital, Civilization Ventures, Innovation Endeavors, Artis Ventures.
Siren Biotechnology is headquartered in San Francisco, United States.
Siren Biotechnology focuses on combining AAV gene therapy with cytokine immunotherapy to develop innovative treatments for cancer.
Siren Biotechnology is at the Grant stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Siren Biotechnology — Funding & Investors." VCBacked, June 26, 2026, https://www.vcbacked.co/company/siren-biotechnology. Accessed July 31, 2026.
VCBacked. (2026). Siren Biotechnology — Funding & Investors. Retrieved July 31, 2026, from https://www.vcbacked.co/company/siren-biotechnology
{{cite web |title=Siren Biotechnology — Funding & Investors |url=https://www.vcbacked.co/company/siren-biotechnology |website=VCBacked |access-date=July 31, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated